Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Sarah Porte(Centre National de la Recherche Scientifique), Bruno Martin(Centre National de la Recherche Scientifique), Amélie Lombès(Délégation Paris 5), Mireille Lambert(Inserm), Cédric Auffray(Délégation Paris 5), Marie‐Clotilde Alves‐Guerra(Centre National de la Recherche Scientifique), Mathieu Germain(Centre National de la Recherche Scientifique), Carole Peyssonnaux(Inserm), Bruno Lucas(Délégation Paris 5), Alexandra Audemard‐Verger(Université de Tours), François Goldwasser(Délégation Paris 5), Rémi Pierre(Centre National de la Recherche Scientifique), Benjamin Saintpierre(Centre National de la Recherche Scientifique), Aurélie Durand(Centre National de la Recherche Scientifique), Renaud Dentin(Centre National de la Recherche Scientifique), Théo Level(Centre National de la Recherche Scientifique), Léa Giraud(Centre National de la Recherche Scientifique), Sophie Vaulont(Délégation Paris 5), Christian Wu(Centre National de la Recherche Scientifique)
Cited by 11
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
|Journal of Clinical Investigation|2007|633
HIF-2α, but not HIF-1α, promotes iron absorption in mice
|Journal of Clinical Investigation|2009|494